Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.
PARP-inhibitors
immune checkpoint inhibitors
neoadjuvant chemotherapy
platinum agents
predictive biomarkers
target therapies
triple-negative breast cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Aug 2022
23 Aug 2022
Historique:
received:
05
07
2022
revised:
09
08
2022
accepted:
16
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
10
9
2022
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is characterized by the absence of hormone receptor and HER2 expression, and therefore a lack of therapeutic targets. Anthracyclines and taxane-based neoadjuvant chemotherapy have historically been the cornerstone of treatment of early TNBC. However, genomic and transcriptomic analyses have suggested that TNBCs include various subtypes, characterized by peculiar genomic drivers and potential therapeutic targets. Therefore, several efforts have been made to expand the therapeutic landscape of early TNBC, leading to the introduction of platinum and immunomodulatory agents into the neoadjuvant setting. This review provides a comprehensive overview of the currently available evidence regarding platinum agents and immune-checkpoint-inhibitors for the neoadjuvant treatment of TNBC, as well as the novel target therapies that are currently being evaluated in this setting. Taking into account the economic issues and the side effects of the expanding therapeutic options, we focus on the potential efficacy biomarkers of the emerging therapies, in order to select the best therapeutic strategy for each specific patient.
Identifiants
pubmed: 36077601
pii: cancers14174064
doi: 10.3390/cancers14174064
pmc: PMC9454536
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
J Natl Cancer Inst. 2018 Jun 1;110(6):628-637
pubmed: 29228315
F1000Res. 2019 Aug 2;8:
pubmed: 31448088
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:46-59
pubmed: 35644793
Clin Cancer Res. 2018 Dec 1;24(23):5820-5829
pubmed: 30061361
Obstet Gynecol. 2017 Oct;130(4):e210-e216
pubmed: 28937575
Radiology. 2006 Apr;239(1):52-60
pubmed: 16484353
Front Oncol. 2020 Dec 23;10:580345
pubmed: 33425733
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
ESMO Open. 2021 Oct;6(5):100276
pubmed: 34597942
Ann Oncol. 2018 Jul 1;29(7):1497-1508
pubmed: 29873695
Cytojournal. 2016 Aug 31;13:18
pubmed: 27651820
J Assist Reprod Genet. 2019 Dec;36(12):2593-2604
pubmed: 31760547
Ann Surg Oncol. 2015 May;22(5):1441-6
pubmed: 25727556
JAMA Oncol. 2020 May 1;6(5):676-684
pubmed: 32053137
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Science. 2019 May 3;364(6439):485-491
pubmed: 31048490
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Horm Cancer. 2015 Dec;6(5-6):206-13
pubmed: 26201402
Int J Cancer. 2018 Apr 1;142(7):1343-1354
pubmed: 29168177
Breast. 2022 Aug;64:7-18
pubmed: 35462344
Br J Cancer. 1999 Jan;79(2):286-92
pubmed: 9888470
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113
pubmed: 34754128
BMC Med. 2016 Jan 04;14:1
pubmed: 26728489
Expert Opin Pharmacother. 2020 Apr;21(6):687-699
pubmed: 32052646
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Int J Environ Res Public Health. 2020 Mar 20;17(6):
pubmed: 32245065
Cancer. 2011 Jun 15;117(12):2747-53
pubmed: 21656753
Cancers (Basel). 2022 Feb 28;14(5):
pubmed: 35267561
Clin Cancer Res. 2021 Feb 15;27(4):975-982
pubmed: 33208340
J Thorac Oncol. 2019 Jul;14(7):e147-e148
pubmed: 31235040
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
Lancet Oncol. 2018 Apr;19(4):497-509
pubmed: 29501363
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Nat Med. 2019 Jun;25(6):920-928
pubmed: 31086347
J Clin Oncol. 2010 Apr 20;28(12):2015-23
pubmed: 20308671
J Clin Oncol. 2020 Feb 10;38(5):388-394
pubmed: 31461380
Breast Cancer Res Treat. 2017 Jan;161(2):279-287
pubmed: 27888421
N Engl J Med. 2016 Jul 7;375(1):23-34
pubmed: 27406347
Clin Cancer Res. 2017 Feb 1;23(3):649-657
pubmed: 27301700
Clin Cancer Res. 2011 Mar 1;17(5):1082-9
pubmed: 21233401
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Ann Oncol. 2016 May;27(5):812-8
pubmed: 27052658
Cancer. 2003 Sep 1;98(5):1055-60
pubmed: 12942575
Nat Med. 2018 May;24(5):628-637
pubmed: 29713086
Nat Commun. 2020 Jun 29;11(1):3272
pubmed: 32601304
Curr Opin Genet Dev. 2017 Feb;42:14-21
pubmed: 28126649
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Breast. 2015 Nov;24 Suppl 2:S36-40
pubmed: 26253813
Ann Oncol. 2020 May;31(5):569-581
pubmed: 32278621
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
Cell Death Differ. 2009 Sep;16(9):1300-2
pubmed: 19684639
NPJ Breast Cancer. 2022 Feb 18;8(1):23
pubmed: 35181659
J Clin Oncol. 2006 Dec 20;24(36):5652-7
pubmed: 17116942
JAMA Oncol. 2020 Sep 1;6(9):1410-1415
pubmed: 32644110
Oncologist. 2020 Apr;25(4):277-278
pubmed: 32091651
Cochrane Database Syst Rev. 2015 Jul 14;(7):CD007058
pubmed: 26171896
BMC Med Genomics. 2011 Jan 09;4:3
pubmed: 21214954
Ann Oncol. 2022 May;33(5):534-543
pubmed: 35182721
Clin Cancer Res. 2013 Oct 1;19(19):5505-12
pubmed: 23965901
J Clin Oncol. 2015 Jan 1;33(1):13-21
pubmed: 25092775
NPJ Breast Cancer. 2018 Aug 6;4:23
pubmed: 30109263
Clin Cancer Res. 2018 Apr 15;24(8):1845-1852
pubmed: 29378733
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
Eur J Cancer. 2021 May;149:134-152
pubmed: 33862496
Oncologist. 2010;15(12):1238-47
pubmed: 21147871
Breast Cancer Res Treat. 2009 May;115(2):423-8
pubmed: 18543098
Breast Cancer Res Treat. 2012 Dec;136(3):795-804
pubmed: 23124476
Lancet Oncol. 2014 Feb;15(2):201-12
pubmed: 24360787
J Clin Oncol. 2015 Jun 10;33(17):1867-9
pubmed: 25918281
Ann Oncol. 2020 Sep;31(9):1216-1222
pubmed: 32461104
Front Oncol. 2021 Jun 28;11:686776
pubmed: 34262869
Clin Cancer Res. 2020 Feb 1;26(3):657-668
pubmed: 31611282
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Sci Transl Med. 2015 Mar 25;7(280):280sr1
pubmed: 25810313
Oncotarget. 2018 May 29;9(41):26406-26416
pubmed: 29899867
Ann Oncol. 2019 Aug 1;30(8):1279-1288
pubmed: 31095287
Nat Rev Cancer. 2004 Oct;4(10):814-9
pubmed: 15510162
J Natl Cancer Inst Monogr. 2001;(30):96-102
pubmed: 11773300
J Clin Oncol. 2018 Mar 20;36(9):884-890
pubmed: 29373071
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
Obstet Gynecol Surv. 1996 Feb;51(2):135-42
pubmed: 8622837
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Ann Oncol. 2012 Aug;23 Suppl 6:vi7-12
pubmed: 23012306
Endocrine. 2020 Sep;69(3):670-681
pubmed: 32507965
J Clin Oncol. 2017 Apr 1;35(10):1049-1060
pubmed: 28135148
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
Ann Oncol. 2020 Mar;31(3):387-394
pubmed: 32067680
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
J Clin Oncol. 2021 Aug 1;39(22):2443-2451
pubmed: 33844595
Cancer Cell. 2021 Jul 12;39(7):989-998.e5
pubmed: 34143979
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Oncologist. 2016 Mar;21(3):283-91
pubmed: 26865589
Cancer Immunol Res. 2017 Feb;5(2):148-156
pubmed: 28039161
Oncotarget. 2021 Mar 02;12(5):394-400
pubmed: 33747355
Front Oncol. 2021 Sep 23;11:736123
pubmed: 34631569
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Oncoimmunology. 2013 Jul 1;2(7):e25444
pubmed: 24073383
Front Oncol. 2020 Oct 09;10:570981
pubmed: 33163401
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Cancer Immunol Immunother. 2021 Aug;70(8):2179-2195
pubmed: 33459842
Obstet Gynecol. 2012 Dec;120(6):1267-72
pubmed: 23168749